Patent · US Active

FGFR3 inhibitor compounds

US11878976B2 · kind B2 · utility

0Cited by

1References

37Claims

0Family size

Assignee

ELI LILLY AND COMPANY · US

Inventors

Adedoyin David ABRAHAM · Thornton, US
Desta Doro BUME · Broomfield, US
Kevin Ronald Condroski · Lafayette, US
Robert Alan HAZLITT · Broomfield, US
Timothy Kercher · Longmont, US
Andrew T. Metcalf · Boulder, US
Kaveri Balan URKALAN · Longmont, US
Shane M. Walls · Lafayette, US
Andrew K. Dilger · Princeton, US

Key dates

Filing date	Mar 3, 2022
Grant date	Jan 23, 2024
Priority date	—
Expiry date	Apr 9, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention provides compounds of the formula: for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.